



Peter Borchmann

Kontakt

Peter Borchmann

Publikationen (8)

van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin C, Kobe C. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial. *BMC cancer* 2022; 22:672.

Kreissl S, Keller U, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Bentz M, Hitz F, Topp M, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, German Hodgkin Study Group. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. *Lancet Haematol* 2021; 8:e398-e409.

Borchmann P, Bentz M, Keller U, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Hitz F, Topp M, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. *Lancet* 2017; 390:2790-2802.

Kreissl S, Borchmann P, Engert A, Diehl V, Fuchs M, Flechtner H, Rueffer J, Shonukan O, Soekler M, Hitz F, Halbsguth T, Behringer K, Brillant C, Mayer A, Goergen H, Mueller H. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. *Lancet Oncol* 2016; 17:1453-1462.

Böll B, Engert A, Diehl V, Fuchs M, Borchmann S, Bürkle C, Eichenauer D, von Tresckow B, Greil R, Kerkhoff A, Hitz F, Bröckelmann P, Behringer K, Goergen H, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. *Blood* 2016; 127:2189-92.

Behringer K, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause S, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, Bentz M, Vieler T, Kriz J, Goergen H, Tanner A, Zijlstra J, Greil R, Markova J, Sasse S, Fuchs M, Topp M, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann H, Schalk E, Semrau R. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. *Lancet* 2014; 385:1418-27.

Borchmann P, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause S, Mueller R, Fuchs M, Rank A, Greil R, Haverkamp H, Diehl V, Cerny T, Markova J, Ho A, Eich H, Mueller-Hermelink H, Kanz L, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. *J Clin Oncol* 2011; 29:4234-42.

Schulz H, Engert A, Diehl V, Schnell R, Borchmann P, Rüdiger T, Driessen C, Elter T, Morschhauser F, Rehwald U, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). *Blood* 2008; 111:109-11.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch